We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,469

The Demise of Valeant Pharmaceuticals: A Case Study in Rotten Culture and Business Ethics
  • Volkov Law Group
  • USA
  • April 3 2016

Showing my age again, Woody Allen’s Take the Money and Run included a hilarious scene when Woody’s parents wearing Groucho Marx glasses talk about


eCommerce Regulation, Bitcoin, Anti-Money Laundering, Shadow Insurance, 401(k) Litigation Expect Focus - Vol. IV, Fall 2015
  • Carlton Fields
  • USA
  • December 23 2015

On January 1, 2016, Section 38.6 of the California Insurance Code will take effect permitting consumers to conduct certain life, disability, and


What Impact Will the New Trump Administration Have on State Attorney General Activity?
  • Jones Day
  • USA
  • January 10 2017

Some state Attorneys General are already expressing their intention to challenge the new Trump Administration ("Administration") as it moves to


Global privacy & data security update vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


Global Privacy & Cybersecurity Update Vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


Advice of counsel defense in US v. Lauren Stevens: dismissal of indictment is not necessarily good news for companies
  • Hogan Lovells
  • USA
  • March 25 2011

The indictment last November of former GlaxoSmithKline (GSK) in-house counsel, Lauren Stevens, for purportedly obstructing a U.S. Food and Drug Administration (FDA) investigation into whether GSK marketed Wellbutrin, an anti-depressant drug, off-label, falsifying and concealing documents, and making false statements sent shockwaves through the legal community


The State AG Report Weekly Update January 7, 2016
  • Cozen O'Connor
  • USA
  • January 7 2016

Kansas AG Derek Schmidt reached a settlement with American Handicapped & Disadvantaged Workers, Inc., (“ADHW”) and its president and CEO for


Funds Talk: December 2016
  • Kramer Levin Naftalis & Frankel LLP
  • European Union, France, United Kingdom, USA
  • December 1 2016

The Office of Compliance Inspections and Examinations (OCIE) announced it is examining registrants' compliance with key whistleblower provisions


Drug and Medical Device Corruption Risks in China
  • Volkov Law Group
  • China, USA
  • March 7 2016

Medical device and pharmaceutical companies know the risks of conducting business in China. Company after company has had to settle FCPA enforcement


Major cases only, please
  • Bracewell LLP
  • USA
  • July 7 2014

At the American Health Lawyers Association meeting last week, Department of Justice officials signaled that the Department may shift to a model of